Skip to content

A clinical trial on Aththikkai chooranam in the management of Madhumega avathaigal I-V(Diabetes mellitus & its complications)

A Prospective Open Labelled ,Non-randomised,Phase-II clinical trial of ATHTHIKKAI CHOORANAM in the management of MADHUMEGA AVATHAIGAL I-V(DIABETES MELLITUS & ITS COMPLICATIONS)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/05/019080
Enrollment
60
Registered
2019-05-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: Aththikkai Chooranam: 72mg/Kg/BW BD B/F with buttermilk for 90 days Control Intervention1: Not applicable: Not applicable

Sponsors

Govt Siddha Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Type II DM patients who were previously diagnosed and having uncontrolled or poorly controlled for more than 2 years duration of illness. 2.Even if patient is having any one amo ng the three a.FBS more than 126mg/dl and within 250mg/dl or b.PPBS more than 200mg/dl and within 350mg/dl or c.HbA1c more than 6.5 and within 10 3.Patients with symptoms of polyuria,polydipsia,polyphagia,asthenia,obedsity(mdetabolic syndrome),numbness,tingling sensation, mood changes and irritability,difficulty in concentration 4.Patients willing to give blood and urine sample before and after the treatment. 5.Willing to participate in study and signing consent by fulfilling the condition of proforma

Exclusion criteria

Exclusion criteria: 1.Type I DM 2.Gestational DM 3.Other specific types of DM 4.Diabetes insipidus 5.Pregnancy 6.Lactating mother 7.Chronic kidney disease 8.Chronic liver disease 9.Ischemic heart disease 10.Other types of neuropathy

Design outcomes

Primary

MeasureTime frame
1.To bring the values of FBS less than 126mg/dl PPBS to less than 200mg/dl and HbA1c to less than 6.5 2.Reduction of the sign and symptoms mentioned in inclusion criteriaTimepoint: 90 days

Secondary

MeasureTime frame
1.Achieving of optimal BMI 2.Achievin g of optimal blood pressureTimepoint: 90 days

Countries

India

Contacts

Public ContactDr A Manoharan MD PhD

Govt Siddha Medical College and Hospital Palayamkottai

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026